APO RESEARCH · REPORT
Diabetic Gastroparesis Treatment
Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes.
Product & engineering
Understand the product.
Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes.
During normal digestion, the stomach contracts to help break down food and move it into the small intestine. Gastroparesis disrupts the stomach’s contraction, which can interrupt digestion. Diabetes can cause gastroparesis due to its effects on the nervous system.
Both type 1 diabetes and type 2 diabetes can cause nerve damage. One of the nerves diabetes may damage is the vagus nerve. The vagus nerve controls the movement of food through the stomach. When the vagus nerve experiences damage, the muscles in the stomach and other parts of the digestive tract are not able to function properly. When this happens, food cannot move as quickly through the digestive system. Gastroparesis is also known as delayed gastric emptying.
Selected research
Industry Research
Diabetic Gastroparesis Treatment Industry Research Report 2026
Market perspective
Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes.
During normal digestion, the stomach contracts to help break down food and move it into the small intestine. Gastroparesis disrupts the stomach’s contraction, which can interrupt digestion. Diabetes can cause gastroparesis due to its effects on the nervous system.
Both type 1 diabetes and type 2 diabetes can cause nerve damage. One of the nerves diabetes may damage is the vagus nerve. The vagus nerve controls the movement of food through the stomach. When the vagus nerve experiences damage, the muscles in the stomach and other parts of the digestive tract are not able to function properly. When this happens, food cannot move as quickly through the digestive system. Gastroparesis is also known as delayed gastric emptying.
Read the full market overview
Market is not concentrated. Sumitomo, Johnson & Johnson, Sanofi are the leaders of the industry, and hold the key technologies and patent, with high-end customers. Top 3 manufacturer accounted for 7.4% market share in 2019.
Report Scope
This report quantifies the global Diabetic Gastroparesis Treatment market in terms of revenue (US$ million) and, where applicable, service volume (), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Diabetic Gastroparesis Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Diabetic Gastroparesis Treatment Market by Company
Sumitomo
Johnson & Johnson
Sanofi
Medtronic
Pfizer
Teva
Boston Scientific
Diabetic Gastroparesis Treatment Segment by Type
Drugs
Surgical Treatment Products
Diabetic Gastroparesis Treatment Segment by Application
Hospital Pharmacies
Private Clinics
Drug Stores
E-Commerce
Diabetic Gastroparesis Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetic Gastroparesis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diabetic Gastroparesis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetic Gastroparesis Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Diabetic Gastroparesis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Drugs
- Surgical Treatment Products
Applications
- Hospital Pharmacies
- Private Clinics
- Drug Stores
- E-Commerce
Companies covered
- Sumitomo
- Johnson & Johnson
- Sanofi
- Medtronic
- Pfizer
- Teva
- Boston Scientific
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Diabetic Gastroparesis Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Drugs
- 2.2.3 Surgical Treatment Products
- 2.3 Diabetic Gastroparesis Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital Pharmacies
- 2.3.3 Private Clinics
- 2.3.4 Drug Stores
- 2.3.5 E-Commerce
- 2.4 Assumptions and Limitations
3 Diabetic Gastroparesis Treatment Breakdown Data by Type
- 3.1 Global Diabetic Gastroparesis Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Diabetic Gastroparesis Treatment Forecasted Market Size by Type (2027-2032)
4 Diabetic Gastroparesis Treatment Breakdown Data by Application
- 4.1 Global Diabetic Gastroparesis Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Diabetic Gastroparesis Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Diabetic Gastroparesis Treatment Market Perspective (2021-2032)
- 5.2 Global Diabetic Gastroparesis Treatment Growth Trends by Region
- 5.2.1 Global Diabetic Gastroparesis Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Diabetic Gastroparesis Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Diabetic Gastroparesis Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Diabetic Gastroparesis Treatment Market Dynamics
- 5.3.1 Diabetic Gastroparesis Treatment Industry Trends
- 5.3.2 Diabetic Gastroparesis Treatment Market Drivers
- 5.3.3 Diabetic Gastroparesis Treatment Market Challenges
- 5.3.4 Diabetic Gastroparesis Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Diabetic Gastroparesis Treatment Players by Revenue
- 6.1.1 Global Top Diabetic Gastroparesis Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Diabetic Gastroparesis Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Diabetic Gastroparesis Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Diabetic Gastroparesis Treatment Head Office and Area Served
- 6.4 Global Diabetic Gastroparesis Treatment Players, Product Type & Application
- 6.5 Global Diabetic Gastroparesis Treatment Manufacturers Established Date
- 6.6 Global Diabetic Gastroparesis Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Diabetic Gastroparesis Treatment Market Size (2021-2032)
- 7.2 North America Diabetic Gastroparesis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Diabetic Gastroparesis Treatment Market Size by Country (2021-2026)
- 7.4 North America Diabetic Gastroparesis Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Diabetic Gastroparesis Treatment Market Size (2021-2032)
- 8.2 Europe Diabetic Gastroparesis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Diabetic Gastroparesis Treatment Market Size by Country (2021-2026)
- 8.4 Europe Diabetic Gastroparesis Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Diabetic Gastroparesis Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Diabetic Gastroparesis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Diabetic Gastroparesis Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Diabetic Gastroparesis Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Diabetic Gastroparesis Treatment Market Size (2021-2032)
- 10.2 South America Diabetic Gastroparesis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Diabetic Gastroparesis Treatment Market Size by Country (2021-2026)
- 10.4 South America Diabetic Gastroparesis Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Diabetic Gastroparesis Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Diabetic Gastroparesis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Diabetic Gastroparesis Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Diabetic Gastroparesis Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sumitomo
- 12.1.1 Sumitomo Company Information
- 12.1.2 Sumitomo Business Overview
- 12.1.3 Sumitomo Revenue in Diabetic Gastroparesis Treatment Business (2021-2026)
- 12.1.4 Sumitomo Diabetic Gastroparesis Treatment Product Portfolio
- 12.1.5 Sumitomo Recent Developments
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Revenue in Diabetic Gastroparesis Treatment Business (2021-2026)
- 12.2.4 Johnson & Johnson Diabetic Gastroparesis Treatment Product Portfolio
- 12.2.5 Johnson & Johnson Recent Developments
- 12.3 Sanofi
- 12.3.1 Sanofi Company Information
- 12.3.2 Sanofi Business Overview
- 12.3.3 Sanofi Revenue in Diabetic Gastroparesis Treatment Business (2021-2026)
- 12.3.4 Sanofi Diabetic Gastroparesis Treatment Product Portfolio
- 12.3.5 Sanofi Recent Developments
- 12.4 Medtronic
- 12.4.1 Medtronic Company Information
- 12.4.2 Medtronic Business Overview
- 12.4.3 Medtronic Revenue in Diabetic Gastroparesis Treatment Business (2021-2026)
- 12.4.4 Medtronic Diabetic Gastroparesis Treatment Product Portfolio
- 12.4.5 Medtronic Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Diabetic Gastroparesis Treatment Business (2021-2026)
- 12.5.4 Pfizer Diabetic Gastroparesis Treatment Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 Teva
- 12.6.1 Teva Company Information
- 12.6.2 Teva Business Overview
- 12.6.3 Teva Revenue in Diabetic Gastroparesis Treatment Business (2021-2026)
- 12.6.4 Teva Diabetic Gastroparesis Treatment Product Portfolio
- 12.6.5 Teva Recent Developments
- 12.7 Boston Scientific
- 12.7.1 Boston Scientific Company Information
- 12.7.2 Boston Scientific Business Overview
- 12.7.3 Boston Scientific Revenue in Diabetic Gastroparesis Treatment Business (2021-2026)
- 12.7.4 Boston Scientific Diabetic Gastroparesis Treatment Product Portfolio
- 12.7.5 Boston Scientific Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst